Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

CBD-OS · JZP926

Other · developed by Jazz Pharmaceuticals

Phase 3 Most advanced trial

JAZZ Developer

1 Registered trials

What is CBD-OS?

CBD-OS (JZP926) is an oral solution formulation studied in developmental and epileptic encephalopathy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: JZP926
Drug type: Other
Therapy area: Neurology
Developer: Jazz Pharmaceuticals (JAZZ)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07723976	Phase 3	Developmental and Epileptic Encephalopathy (DEE)	Not yet recruiting	JAZZ

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Developmental and Epileptic Encephalopathy (DEE)

More from Jazz Pharmaceuticals

Asparaginase Erwinia chrysanthemi FDA approved Calcium, Magnesium, Potassium, And Sodium Oxybates FDA approved Daunorubicin And Cytarabine Liposome FDA approved Defibrotide FDA approved Lurbinectedin FDA approved Zanidatamab FDA approved Flezurafenib Phase 1 JZP269 Phase 1 JZP926 Phase 2/3 Nabiximols Phase 2 ONC206 Phase 2

Sources

ClinicalTrials.gov NCT07723976

Updated Oct 3, 2026. Something wrong or missing? Report it on the JAZZ page.

Follow JAZZ, the company behind CBD-OS

See JAZZ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

JAZZ catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z